The identical active ingredient, tirzepatide, is marketed under different brands, Mounjaro and Zepbound, depending on their approved use for diabetes or weight loss, complicating access and pricing for patients.
Mounjaro has become one of the most talked-about injections in medicine, but the branding still causes confusion. According to the FDA, Mounjaro contains tirzepatide and was approved in May 2022 for adults with type 2 diabetes. The same active ingredient later reappeared under a different name, Zepbound, which the FDA approved in November 2023 for chronic weight management in adults with obesity or overweight who also have weight-related conditions. In practice, that means the same molecule can be prescribed under different labels depending on the diagnosis.
That distinction matters because it shapes both access and price. WebMD notes that Mounjaro is the diabetes brand, while Zepbound is the weight-loss brand, even though both rely on tirzepatide. Lilly’s own pricing and savings programmes have added to the divide, with coverage often depending less on the drug itself than on the condition listed by the prescriber. For many patients, the biggest obstacle is not whether the treatment works, but whether insurance will treat it as diabetes care or obesity care.
Tirzepatide works by activating two hormone pathways, GLP-1 and GIP, which help regulate appetite, digestion and blood sugar. That dual action has made it one of the most effective medicines in the class. Clinical data cited in the source material show average weight loss of roughly 20% to 22% at higher doses, alongside major improvements in blood sugar control for people with diabetes. Head-to-head studies have generally favoured tirzepatide over semaglutide on weight and glucose outcomes, although semaglutide has stronger cardiovascular evidence at present.
The early weeks can be disappointing for people expecting an immediate transformation. The starting dose is designed mainly to help the body adjust, rather than to deliver the full effect straight away. Dose increases are typically gradual, which is one reason side effects are often worst at the beginning and after each step-up. Nausea, diarrhoea, vomiting and constipation are the most common problems, and the FDA has also kept boxed and class warnings in place for more serious risks, including thyroid tumours seen in animal studies, as well as concerns such as pancreatitis, gallbladder trouble and delayed stomach emptying.
The practical questions are often the ones patients ask last: who should use it, and what will it cost? The FDA says Zepbound is meant to be used alongside diet and physical activity, while Mounjaro remains a diabetes treatment. That separation matters for anyone trying to understand why one person pays a small co-pay and another faces a steep cash price for essentially the same injection. For patients weighing the options, the real decision is not simply which brand is strongest, but which one fits their diagnosis, medical history, risk profile and budget.
Disclaimer: This content is for informational purposes only and is not intended to be a substitute for professional medical judgment, advice, diagnosis, or treatment.
